Abivax to Participate in Upcoming Fall Investor Conferences

Abivax to Participate in Upcoming Fall Investor Conferences

PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences:

Guggenheim Healthcare Innovation Conference
Boston, Massachusetts
November 9-11, 2026
Fireside Chat: Tuesday, November 10^th, 10:30-10:55am ET

LifeSci Capital X Sofinnova Growth & Innovation Summit
London, United Kingdom
November 16, 2026

30^th German Equity Forum (Deutsches Eigenkapitalforum)
Frankfurt, Germany
November 23-25, 2026
Corporate Presentation: Monday, November 23^rd, 11:40am-12:10pm CET

Evercore ISI 9^th Annual Healthcare Conference
Miami, Florida
November 30 – December 2, 2026
Fireside Chat: Wednesday, December 2^nd, 7:55-8:15am ET

Piper Sandler 38^th Annual Healthcare Conference
New York, New York
December 1-3, 2026
Fireside Chat: Thursday, December 3^rd, 8:00-8:25am ET

Webcast links for select presentations will be available in the Investors section of Abivax’s website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company’s website for a limited time following the conference.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Abivax SA
Patrick Malloy
SVP, Investor Relations
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications

Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

Attachment

• 20261102_Abivax_PR_Fall Investor Conferences